Chronische Nierschade - Kwaliteitskoepel

kwaliteitskoepel.nl
  • No tags were found...

Chronische Nierschade - Kwaliteitskoepel

Richtlijn Chronische Nierschade, 2009138. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss ofrenal function in people with moderate chronic renal insufficiency and cardiovasculardisease. J Am Soc Nephrol 2003; 14: 1605-1613139. Tonelli M, Isles C, Craven T et al. Effect of pravastatin on rate of kidney function lossin people with or at risk for coronary disease. Circulation 2005; 112: 171-178140. Vita G, Toscano A, Mileto G et al. Bezafibrate-induced myopathy: no evidence fordefects in muscle metabolism. Eur Neurol 1993; 33: 168-172141. Chow LT, Chow WH. Gemfibrozil induced myositis: a case report with lightmicroscopic and ultrastructural study. Chin Med Sci J 1994; 9: 129-131142. Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC. Gemfibrozil for secondaryprevention of cardiovascular events in mild to moderate chronic renal insufficiency.Kidney Int 2004; 66: 1123-1130143. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensinconvertingenzyme inhibitor therapy in patients with end-stage renal disease and anacute myocardial infarction. J Am Coll Cardiol 2003; 42: 201-208144. Krause MW, Massing M, Kshirsagar A, Rosamond W, Simpson RJ, Jr. Combinationtherapy improves survival after acute myocardial infarction in the elderly with chronickidney disease. Ren Fail 2004; 26: 715-725145. McCullough PA, Sandberg KR, Borzak S, Hudson MP, Garg M, Manley HJ. Benefitsof aspirin and beta-blockade after myocardial infarction in patients with chronickidney disease. Am Heart J 2002; 144: 226-232146. Gerrah R, Ehrlich S, Tshori S, Sahar G. Beneficial effect of aspirin on renal functionin patients with renal insufficiency postcardiac surgery. J Cardiovasc Surg (Torino)2004; 45: 545-550147. Baigent C, Landray M, Leaper C et al. First United Kingdom Heart and RenalProtection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin andsafety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 2005; 45: 473-484148. Hansen HP, Gaede PH, Jensen BR, Parving HH. Lack of impact of low-doseacetylsalicylic acid on kidney function in type 1 diabetic patients withmicroalbuminuria. Diabetes Care 2000; 23: 1742-1745149. Ogawa H, Nakayama M, Morimoto T et al. Low-dose aspirin for primary preventionof atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.JAMA 2008; 300: 2134-2141150. Belch J, MacCuish A, Campbell I et al. The prevention of progression of arterialdisease and diabetes (POPADAD) trial: factorial randomised placebo controlled trialof aspirin and antioxidants in patients with diabetes and asymptomatic peripheralarterial disease. BMJ 2008; 337: a184040

More magazines by this user
Similar magazines